Bull, Bear & Beyond – BB Biotech in 60 seconds

Edison recently released a report on BB Biotech. The biotech sector has been hit by uncertainties about the economic outlook, US tariffs and the regulatory policies of the new US administration. This has increased market volatility, especially in the small- and mid-cap companies that BB Biotech favours, and performance has declined accordingly. Yet the news is not all bad. The company’s portfolio holdings are performing well, with several delivering regulatory and clinical milestones. BB Biotech’s manager has taken action to protect returns by increasing the focus on larger-cap names and enhancing risk management. And lower valuations have created opportunities for him to gain exposure to more high-quality companies. Most importantly, the biotech sector still has a very positive long-term outlook, with commensurate rewards for those willing to wait out near-term volatility.

Listen on your preferred podcast player below:

• Apple Podcast
• Spotify
• YouTube
• Zencastr

About Bull, Bear & Beyond: Each episode features candid conversations with senior executives and from our own team of experts from across industries, exploring strategy, innovation, and the opportunities shaping their markets and 60-second pieces are a compressed summary of content designed to convey our message in a single, easily shareable hit.